Investigational drug · Phase 2
CVL006
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "CVL006"
First trial start
2025
Sep 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CVL006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CVL006" as an intervention, largest first.
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
- CVL006 Combination Therapy in Advanced Solid TumorsNot yet recruiting
Convalife (Shanghai) Co., Ltd.Industry
NCT07157956 · 318 participants (planned) · Start Sep 10, 2025 · Primary completion Aug 12, 2028
Drug: CVL006 combined with pemetrexed and carboplatin; CVL006 in combination with SKB264 and 2 more · For: Advanced Solid Tumor
Sites: Guangzhou, China
- Clinical Study of CVL006 Injection in Advanced Solid TumorsNot yet recruiting
Convalife (Shanghai) Co., Ltd.Industry
NCT06621615 · 120 participants (planned) · Start Nov 20, 2024 · Primary completion May 20, 2028
Drug: CVL006 Injection · For: Advanced Solid Tumor
- Clinical Study of CVL006 Combination With 9MW2821Not yet recruiting
Convalife (Shanghai) Co., Ltd.Industry
NCT07615660 · 108 participants (planned) · Start May 15, 2026 · Primary completion Apr 30, 2029
Drug: CVL006 in combination with 9MW2821; CVL006 in combination with 9MW2821 · For: Advanced Solid Tumor
Newest research
PubMed records naming it or its code names, newest first.
- A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy.
Wang C, Huang H, Song Z, et al. · Antib Ther 2025
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.